Pro Bono Bio TM is a new international pharmaceutical company that launched today. Pro Bono Bio is the result of a three year Anglo/Russian project, developed by Celtic Pharma Holdings in London. Pro ...

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia Subcutaneous blood factors expected to revolutionise ...

LONDON – A new Anglo-Russian biopharmaceutical company has been formed with $300 million from the Russian government, matched by a further $300 million from investors in the London-based private ...

Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the ...

> Pro Bono Bio has completed its first series of trials of subcutaneous treatments for hemophilia, showing that the therapies improve blood clotting for extended periods. These would make ...

LONDON (Reuters) - The Russian government has become the leading shareholder in a new Anglo-Russian drug company with an unusual mission to develop nanotechnology, help the world's poor -- and list in ...

There's a rumor going round the exhibition hall that Bono made an unannounced visit yesterday morning. Our very own director of business development, Jeremy Abbate, told me that Bono was walking ...

Imperial Innovations Group plc (AIM: IVO, 'Innovations'), a leading technology commercialisation and investment group, announces that portfolio company PolyTherics, a provider of solutions for the ...